A new code has been created to capture complications of immune effector cellular (IEC) therapy with the corresponding seventh characters for initial encounter, subsequent encounter and sequela as follows:
Immune effector cells have the ability to modulate or effect an immune response. B cells, dendritic cells, natural killer cells, and T cells are collected from the patient, transformed into a therapeutic product, and then administered back into the patient. These cellular therapy products are part of an innovative cancer treatment called immunotherapy, in which the patient’s immune system attacks the malignancy. Although immunotherapy has improved outcomes for pediatric and adult patients, this treatment may be toxic for some patients, causing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). As IEC therapies, especially chimeric antigen receptor (CAR) T-cell therapy, become more widely used, there is a need for standardized toxicity management.
When reporting codes for complications of IEC therapy, assign an additional code to describe the specific complication, such as CRS or ICANS. The creation of this code will help to facilitate improved data collection and track outcomes.